0000899243-20-032458.txt : 20201202 0000899243-20-032458.hdr.sgml : 20201202 20201202094822 ACCESSION NUMBER: 0000899243-20-032458 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201202 FILED AS OF DATE: 20201202 DATE AS OF CHANGE: 20201202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chao Jennifer M CENTRAL INDEX KEY: 0001639625 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 201362596 MAIL ADDRESS: STREET 1: 7 PURITAN WOODS ROAD CITY: RYE STATE: NY ZIP: 10580 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 302-842-8450 MAIL ADDRESS: STREET 1: 2 RIGHTER PARKWAY, SUITE 200 CITY: WILMINGTON STATE: DE ZIP: 19803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-02 1 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001639625 Chao Jennifer M C/O BIOSPECIFICS TECHNOLOGIES CORP. 2 RIGHTER PKWY, DE CORP CENTER II WILMINGTON DE 19803 1 0 0 0 Common Stock, $0.001 par value 2020-12-02 4 D 0 1920 D 1726 D Common Stock, $0.001 par value 2020-12-02 4 D 0 1726 D 0 D Stock Option (Right to Buy) 37.64 2020-12-02 4 D 0 1687 50.86 D 2025-04-22 Common Stock 1687 20000 D Stock Option (Right to Buy) 41.82 2020-12-02 4 D 0 15000 46.68 D 2028-03-15 Common Stock 15000 5000 D Stock Option (Right to Buy) 55.62 2020-12-02 4 D 0 5000 32.88 D 2030-03-13 Common Stock 5000 0 D Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 1,920 shares of common stock were exchanged for a cash payment of $169,920.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person. Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50). Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (April 22, 2015), were canceled in exchange for a cash payment of $85,800.82, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (March 15, 2018), were canceled in exchange for a cash payment of $700,200.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which would have vested in full on the one-year anniversary of the grant date (March 13, 2020), were canceled in exchange for a cash payment of $164,400.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. /s/ Jennifer M. Chao, by Carl A. Valenstein, attorney-in-fact 2020-12-02